Top Page
EVE Health Group Limited
(Sydney:EVE)
EVE Health Group Limited (EVE) vs. iShares MSCI Australia ETF (EWA)
EVE Health Group Limited Business Overview & Revenue Model
EVE Health Group Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.73M | 1.73M | 2.13M | 2.33M | 2.01M | 2.80M |
| Gross Profit | 824.03K | 824.03K | 876.96K | 827.83K | -1.00M | -713.50K |
| EBITDA | -1.45M | -1.43M | -1.51M | -2.18M | -4.53M | -2.79M |
| Net Income | -1.58M | -1.58M | -1.90M | -4.04M | -5.37M | -3.63M |
Balance Sheet | ||||||
| Total Assets | 4.12M | 4.12M | 2.52M | 4.13M | 8.07M | 11.92M |
| Cash, Cash Equivalents and Short-Term Investments | 903.42K | 903.42K | 106.17K | 192.48K | 1.10M | 3.16M |
| Total Debt | 91.28K | 91.28K | 74.85K | 4.28K | 492.39K | 1.01M |
| Total Liabilities | 572.45K | 572.45K | 1.30M | 1.01M | 1.14M | 1.74M |
| Stockholders Equity | 3.55M | 3.55M | 1.22M | 3.12M | 6.93M | 10.19M |
Cash Flow | ||||||
| Free Cash Flow | -1.62M | -1.62M | -1.11M | -1.65M | -3.80M | -2.51M |
| Operating Cash Flow | -1.62M | -1.62M | -1.11M | -1.65M | -3.77M | -2.24M |
| Investing Cash Flow | 2.13M | 2.13M | 874.27K | 498.46K | -26.05K | -263.38K |
| Financing Cash Flow | 279.09K | 279.09K | 146.37K | 240.69K | 1.74M | 529.43K |
EVE Health Group Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
43 Neutral | AU$30.90M | 36.52 | ― | ― | 6.76% | ― | |
43 Neutral | AU$6.66M | -0.61 | ― | ― | -21.84% | 79.99% | |
42 Neutral | AU$8.01M | -2.78 | -77.48% | ― | 63.30% | 70.00% | |
41 Neutral | AU$5.98M | -1.84 | -60.84% | ― | -18.70% | 20.83% | |
37 Underperform | AU$13.76M | ― | -555.97% | ― | 88.48% | 51.61% |
EVE Health Group Limited Corporate Events
EVE Health Group has transitioned from development to early commercialisation in the December 2025 quarter, with first patient prescriptions of Dyspro™ under Australian regulatory pathways and completion of the initial commercial manufacturing run of Libbo™, which is now in national distribution and positioned for near-term prescribing via telehealth and pharmacies. The company strengthened its clinical and patient engagement infrastructure through a national telehealth patient support agreement with hubMed, launch of the Reclaim My Cycle education and research platform for women with period pain, appointment of its first Medical Science Liaison to drive prescriber education, and a $1.1 million capital raising to accelerate the rollout and regulatory progression of both flagship products, leaving it with $0.9 million in cash and signaling growing investor confidence in its commercialisation strategy.
The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group has completed the first commercial manufacturing run of Libbo, its oral dissolving film treatment for erectile dysfunction, and delivered inventory to a national distribution partner, moving the product from development into commercial launch. With quality-assured stock now integrated into national warehousing, logistics and fulfilment systems, and telehealth prescribing and pharmacy channels in place, the company is positioned for imminent market entry, advancing its men’s health portfolio and underpinning its broader strategy to build scalable, revenue-generating pharmaceutical offerings in the sizable and growing erectile dysfunction treatment market.
The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group Limited has disclosed a change in the shareholding of director Stuart Gunzburg, who acquired 200,000 ordinary shares in the company on 2 January 2026 via an on‑market trade for a total consideration of A$4,200. Following the transaction, Gunzburg’s direct holding remains at 7,936,508 ordinary shares, while his indirect interests through various associated entities increased to 1,180,555 ordinary shares and 1,000,000 unlisted options, signalling a modest increase in his overall equity exposure and aligning his interests more closely with shareholders, though without indicating any broader strategic shift at the company.
The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group Limited announced the issuance of 11,300,000 new unquoted equity securities, specifically options exercisable at 6 cents and expiring on December 31, 2028. This move is part of an employee incentive scheme, which could potentially enhance employee engagement and align their interests with the company’s growth objectives.
The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group Limited has announced the issuance of 22,999,998 unquoted securities, which are options exercisable at 6 cents and set to expire on December 31, 2027. This issuance is part of a previously announced transaction, indicating strategic financial maneuvers that may impact the company’s market positioning and stakeholder interests.
The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group announced that all resolutions proposed at its General Meeting on December 4, 2025, were successfully passed by a poll. This outcome supports the company’s strategic initiatives, including the ratification and approval of various securities and options, which are expected to strengthen its market position and facilitate the commercialization of its innovative pharmaceutical products.
The most recent analyst rating on (AU:EVE) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on EVE Health Group Limited stock, see the AU:EVE Stock Forecast page.
EVE Health Group Limited has announced a change in the director’s interest notice for Stuart Gunzburg. The change involves an off-market transfer of 20,502,645 ordinary shares, which were previously held indirectly through CBLW Pty Ltd. This transfer is part of a Deed of Settlement, and the shares will remain under voluntary escrow until June 12, 2026. This adjustment in shareholding does not involve any cash consideration and reflects a strategic realignment of interests within the company’s leadership.
EVE Health Group Limited has announced the launch of two innovative products: Dyspro, a fast-acting non-hormonal gummy for menstrual pain, and Libbo, a rapid-onset oral strip for erectile dysfunction. These products target the large, underserved global markets for dysmenorrhoea and erectile dysfunction, valued at US$10.92 billion and US$5.31 billion respectively. The company’s patent-pending nano-emulsion technology enhances the speed and effectiveness of these formulations. Dyspro has already been launched in Australia, with Libbo expected to follow in December, marking a significant step in the company’s commercialisation efforts.
EVE Health Group Limited has signed a Patient Support Telehealth Services Agreement with hubMed Pty Ltd to enhance care for patients using its products, Dyspro™ and Libbo™, for women’s and men’s health conditions. This agreement aims to improve continuity of care and patient confidence by providing accessible telehealth consultations with registered nurses, reinforcing the safe use of EVE’s therapies. The initiative is expected to address significant unmet needs in both women’s and men’s health, potentially improving patient outcomes and adherence to treatment.
EVE Health Group Limited has signed a Patient Support Telehealth Services Agreement with hubMed Pty Ltd to enhance care for patients using EVE’s products for women’s and men’s health conditions. This partnership aims to improve continuity of care through regular telehealth consultations, supporting patient adherence and timely clinical guidance. The initiative is expected to strengthen EVE’s market positioning by providing better patient outcomes and expanding their digital ecosystem to support product launches.
EVE Health Group announced that all resolutions presented at its Annual General Meeting were passed by a poll. This includes the adoption of the remuneration report, the re-election of a director, approval of an additional 10% capacity, and the issuance of securities under an employee incentive plan. These decisions reflect strong shareholder support and could positively impact the company’s strategic initiatives and market positioning.
EVE Health Group Limited has announced a General Meeting of Shareholders to be held on December 4, 2025, in Subiaco, Western Australia. Shareholders are encouraged to participate by attending in person or voting by proxy, with proxy forms to be submitted 48 hours prior to the meeting. This meeting is a crucial event for shareholders to engage with the company’s governance and decision-making processes.
EVE Health Group Limited has announced the issuance of up to 12,300,000 unlisted options to key personnel and directors as part of its Employee Incentive Plan. This initiative aims to align compensation with shareholder value creation, support talent retention, and focus on achieving key commercial and regulatory milestones in its health portfolios. The options, which require shareholder approval for directors, have specific vesting conditions tied to service and performance targets, including share price milestones and product registrations.
EVE Health Group Limited has appointed its first dedicated Medical Science Liaison (MSL) to lead national medical education and engagement programs, marking a significant step in its commercial rollout strategy. This appointment aims to build confidence among prescribers and broaden patient access to EVE’s products, Dyspro™ and Libbo™, with plans to expand the MSL team throughout 2026, enhancing the company’s medical capability and supporting its growth in the pharmaceutical industry.
EVE Health Group Limited announced significant progress in the commercial rollout of its products Dyspro™ and Libbo™. The company has completed the first patient prescriptions for Dyspro™, a cannabinoid-based gummy for women’s health issues, and placed its first commercial order for Libbo™, an oral dissolving film for erectile dysfunction. EVE has also launched an online platform, Reclaim My Cycle, to support women’s health education and prescriber resources. Additionally, a $1.1 million placement was completed to accelerate these initiatives, and a Scientific Advisory Board was established to guide the company’s evidence-based strategy.